CTI Molecular Imaging Subsidiary, PETNET Solutions, Announces Management Agreement with Johns Hopkins Healthcare; PETNET and Johns Hopkins Healthcare to Partner in the operation of the existing PET production and research facility at Johns Hopkins University.CTI (Computer Telephone Integration) Combining data with voice systems in order to enhance telephone services. For example, automatic number identification (ANI) allows a caller's records to be retrieved from the database while the call is routed to the appropriate party. Molecular Imaging, Inc. , a leading provider of positron emission tomography positron emission tomography: see PET scan. positron emission tomography (PET) Imaging technique used in diagnosis and biomedical research. (PET) equipment, molecular probes Molecular Probes is a biotechnology company located in Eugene, Oregon specializing in fluorescence. The company was founded in 1975 by Richard and Rosaria Haugland in their kitchen in Minnesota, then moved briefly to Texas and finally to Oregon in the early 1980s. and services, today announced an agreement between its subsidiary PETNET Solutions and Johns Hopkins Healthcare (JHHC) for the management of the production and distribution of clinical PET radiopharmaceuticals produced at the existing JHHC PET cyclotron cyclotron: see particle accelerator. cyclotron Particle accelerator that accelerates charged atomic or subatomic particles in a constant magnetic field. production facility. PETNET and JHHC have agreed to partner in the operation of a production facility located at Johns Hopkins University Johns Hopkins University, mainly at Baltimore, Md. Johns Hopkins in 1867 had a group of his associates incorporated as the trustees of a university and a hospital, endowing each with $3.5 million. Daniel C. . As part of the agreement, PETNET will manage the existing production facility and supply PET isotopes to the surrounding market as well as help support some of Johns Hopkins' existing PET clinical and research programs. "The agreement with Johns Hopkins will help expand the distribution capabilities and market presence of our PETNET Solutions subsidiary within the greater Baltimore area. We are also pleased to be working with Johns Hopkins, one of the preeminent research organizations in the world, in supporting their PET programs," said Thomas J. Hook, President, CTI Solutions Group. About CTI: CTI Molecular Imaging, Inc. is a leading supplier of products and services for positron emission tomography (PET), a diagnostic imaging technology used in the detection and treatment of cancer, cardiac disease and neurological disorders. Additional information is available at: http://www.ctimi.com/ . About PET and PET/CT PET/CT Positron Emission Tomography and Computed Tomography : PET images the biology of diseases at the molecular level, often before changes are visible by anatomical imaging or, in many cases, before symptoms appear. Diseases are biological processes and it is these processes that PET examines. PET/CT is a new imaging technology that combines the biological examination of patients by PET with the CT images of the body's structural detail. PET/CT technology improves the diagnostic accuracy and treatment management of patients by providing surgeons, radiation oncologists and other physicians precise anatomical landmarks associated with the disease condition as determined by PET. PET's whole-body imaging capability helps physicians improve their ability to detect and determine the location, extent and stage of cancer, neurological disorders and cardiac disease. By improving diagnosis, PET scans aid physicians in selecting better courses of treatment, as well as assessing whether treatment is effective or should be changed. Recent published clinical trials have shown that in a wide array of cancers, the use of PET has caused the treatment to be changed for 15 to 50% of patients, depending on the specific clinical question. In addition, PET and PET/CT provide both the patient and their physician with a degree of certainty that is often unavailable through other imaging methods.
Contact: CTI Molecular Imaging, Inc., Knoxville, TN
Michael A. Lawless, 865-218-2000
Certain matters discussed in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such forward-looking statements may be identified by words such as "believe," "assume," "expect," "anticipate," "intend," "estimate" or similar expressions, and any other statements that necessarily depend on future events. Forward-looking statements involve a number of risks and uncertainties and there can be no assurance that any forward-looking statements will prove to be accurate. Various factors could cause actual results to differ materially from those anticipated in the forward-looking statements. CTI undertakes no obligation to update or revise any forward- looking statements. Further information regarding risks, uncertainties and other factors that could adversely affect CTI or cause actual results to differ materially from those anticipated in forward-looking statements are included in CTI's Annual Report on Form 10-K for the fiscal year ended September 30, 2003, Quarterly Reports on Form 10-Q, and in other reports CTI files with the SEC. CONTACT: Michael A. Lawless of CTI Molecular Imaging, Inc., +1-865-218-2000 Web site: http://www.ctimi.com/ |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion